“…Intranasal decongestants usually do not cause systemic sympathomimetic symptoms; however, a variety of cerebrovascular adverse events have been reported, including anterior ischemic optic neuropathy, 920 stroke, 921 branch retinal artery occlusion, 922 and ''thunderclap'' vascular headache. 923,924 Caution for use of decongestants during the first trimester is recommended because fetal heart rate changes with administration during pregnancy 925 have been reported. Topical vasoconstrictors should be used with care below age 1 year because of the narrow margin between the therapeutic and toxic dose, which increases the risk for cardiovascular and CNS side effects.…”